NervGen Pharma: Clinical Trials

3 trials sponsored by NervGen Pharma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 recruiting. 2 Phase 1, 1 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 12Completed 2
Phase 21Completed 1
Phase 31Recruiting 1

Follow NervGen Pharma: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury
NVG-291, Placebo - Chronic Spinal Cord Injury
Phase 3RecruitingNervGen Pharma1502026-09-282026-11-06
NVG-291 in Spinal Cord Injury Subjects
NVG-291, Placebo Injection - Spinal Cord Injuries, Chronic Spinal Cord Injury
Phase 1 / Phase 2CompletedNervGen Pharma242023-08-082026-11-20
A Phase I Safety Study of NVG-291 in Healthy Adults
NVG-291, Placebo - Spinal Cord Injury
Phase 1CompletedNervGen Pharma742021-05-062024-01-10

Conditions studied

Spinal Cord Injuries (2)  ·  Quadriplegia (1)

Countries

United States (2)  ·  Australia (1)  ·  Canada (1)

Top investigators

Daniel Miko, MD (1)  ·  Randall Kaye, M.D. (1)

Results publications

PMID 40744729